FI3571192T3 - Jak1-selektiivisiä inhibiittoreita - Google Patents
Jak1-selektiivisiä inhibiittoreita Download PDFInfo
- Publication number
- FI3571192T3 FI3571192T3 FIEP18701296.8T FI18701296T FI3571192T3 FI 3571192 T3 FI3571192 T3 FI 3571192T3 FI 18701296 T FI18701296 T FI 18701296T FI 3571192 T3 FI3571192 T3 FI 3571192T3
- Authority
- FI
- Finland
- Prior art keywords
- fluoro
- indol
- amino
- phenyl
- methylsulfonyl
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 18
- -1 methylpiperazin-1-yl Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- JNUZADQZHYFJGW-JOCHJYFZSA-N (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide Chemical compound FC=1C(=NC(=NC=1)NC1=C(C(=CC=C1)S(=O)(=O)C)F)C1=CNC2=C(C=CC=C12)NC([C@@H](COC)N1CCN(CC1)C)=O JNUZADQZHYFJGW-JOCHJYFZSA-N 0.000 claims 2
- RKWROPQYAYAFFY-UHFFFAOYSA-N 2-methoxy-2-(4-methylpiperazin-1-yl)propanamide Chemical compound COC(C(=O)N)(C)N1CCN(CC1)C RKWROPQYAYAFFY-UHFFFAOYSA-N 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010040844 Skin exfoliation Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- AXCUQYSFMVWWKV-GDLZYMKVSA-N (2R)-N-[3-[2-(2-fluoro-3-methylsulfonylanilino)-5-methylpyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)-3-phenylmethoxypropanamide Chemical compound C(C1=CC=CC=C1)OC[C@H](C(=O)NC=1C=CC=C2C(=CNC=12)C1=NC(=NC=C1C)NC1=C(C(=CC=C1)S(=O)(=O)C)F)N1CCN(CC1)C AXCUQYSFMVWWKV-GDLZYMKVSA-N 0.000 claims 1
- KZBWLTMGNRKWRE-XMMPIXPASA-N (2R)-N-[3-[2-(2-fluoro-3-methylsulfonylanilino)-5-methylpyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methyl-1,4-diazepan-1-yl)propanamide Chemical compound COC[C@@H](N1CCCN(C)CC1)C(=O)NC1=C2NC=C(C2=CC=C1)C1=C(C)C=NC(NC2=C(F)C(=CC=C2)S(C)(=O)=O)=N1 KZBWLTMGNRKWRE-XMMPIXPASA-N 0.000 claims 1
- IKKOCBJSXASHMI-LJQANCHMSA-N (2R)-N-[3-[2-(3-cyclopropylsulfonyl-2-fluoroanilino)-5-methylpyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide Chemical compound C1(CC1)S(=O)(=O)C=1C(=C(C=CC=1)NC1=NC=C(C(=N1)C1=CNC2=C(C=CC=C12)NC([C@@H](C)N1CCN(CC1)C)=O)C)F IKKOCBJSXASHMI-LJQANCHMSA-N 0.000 claims 1
- WOGXHNJBKGZMHV-UHFFFAOYSA-N 2-methoxypropanamide Chemical compound COC(C)C(N)=O WOGXHNJBKGZMHV-UHFFFAOYSA-N 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447057P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051038 WO2018134213A1 (en) | 2017-01-17 | 2018-01-16 | Jak1 selective inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3571192T3 true FI3571192T3 (fi) | 2023-03-06 |
Family
ID=61024756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18701296.8T FI3571192T3 (fi) | 2017-01-17 | 2018-01-16 | Jak1-selektiivisiä inhibiittoreita |
Country Status (39)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX390625B (es) * | 2017-01-17 | 2025-03-19 | Astrazeneca Ab | Inhibidores selectivos de jak1. |
| JP6608565B2 (ja) * | 2017-01-26 | 2019-11-20 | ハンミ ファーマシューティカルズ カンパニー リミテッド | ピリミジン化合物及びその医薬用途 |
| CN118580223A (zh) * | 2018-07-18 | 2024-09-03 | 阿斯利康(瑞典)有限公司 | 抑制jak的化合物的昔萘酸盐 |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| CN112823159B (zh) * | 2018-09-21 | 2024-03-01 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| MX2021012749A (es) * | 2019-04-19 | 2021-11-18 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidor selectivo de la jak1 cinasa. |
| AU2020308814A1 (en) | 2019-06-27 | 2022-02-03 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents |
| CN115916764B (zh) * | 2020-04-09 | 2024-09-20 | 达萨玛治疗公司 | 作为sarm1抑制剂的吲唑衍生物 |
| CN114269736B (zh) * | 2020-11-26 | 2024-02-02 | 科辉智药(深圳)新药研究中心有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| WO2024150110A1 (en) * | 2023-01-11 | 2024-07-18 | Pfizer Inc. | Compositions and methods for the treatment and/or prevention of type 1 diabetes |
| CN115974845B (zh) * | 2023-01-19 | 2024-09-20 | 奥锐特药业股份有限公司 | 奥希替尼中间体的制备方法 |
| US20240307353A1 (en) * | 2023-03-16 | 2024-09-19 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of asthma |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044457A1 (en) * | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
| EP2114876A4 (en) | 2007-02-05 | 2010-12-22 | Amira Pharmaceuticals Inc | INVERSE INDOLES AS INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATION PROTEIN (FLAP) |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| US20100298343A1 (en) | 2007-10-05 | 2010-11-25 | John Howard Hutchinson | 5-lipoxygenase-activating protein (flap) inhibitors |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| SMT201800137T1 (it) | 2010-03-10 | 2018-07-17 | Incyte Holdings Corp | Derivati di piperidin-4-il azetidina come inibitori di jak1 |
| BR112013006016A2 (pt) * | 2010-09-15 | 2016-06-07 | Hoffmann La Roche | compostos de azabenzotiazol, composições e métodos de uso |
| EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| KR20250035597A (ko) * | 2015-09-25 | 2025-03-12 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
| MX390625B (es) | 2017-01-17 | 2025-03-19 | Astrazeneca Ab | Inhibidores selectivos de jak1. |
-
2018
- 2018-01-16 MX MX2019008435A patent/MX390625B/es unknown
- 2018-01-16 CN CN201880018044.3A patent/CN110461830B/zh active Active
- 2018-01-16 PE PE2019001401A patent/PE20191108A1/es unknown
- 2018-01-16 RS RS20230130A patent/RS63981B1/sr unknown
- 2018-01-16 LT LTEPPCT/EP2018/051038T patent/LT3571192T/lt unknown
- 2018-01-16 MA MA47301A patent/MA47301B1/fr unknown
- 2018-01-16 FI FIEP18701296.8T patent/FI3571192T3/fi active
- 2018-01-16 PH PH1/2019/501639A patent/PH12019501639B1/en unknown
- 2018-01-16 WO PCT/EP2018/051038 patent/WO2018134213A1/en not_active Ceased
- 2018-01-16 EP EP22209765.1A patent/EP4219470A1/en active Pending
- 2018-01-16 PT PT187012968T patent/PT3571192T/pt unknown
- 2018-01-16 CA CA3049175A patent/CA3049175A1/en active Pending
- 2018-01-16 MY MYPI2019004083A patent/MY199735A/en unknown
- 2018-01-16 DK DK18701296.8T patent/DK3571192T3/da active
- 2018-01-16 HU HUE18701296A patent/HUE061064T2/hu unknown
- 2018-01-16 PL PL18701296.8T patent/PL3571192T3/pl unknown
- 2018-01-16 US US16/478,168 patent/US10961228B2/en active Active
- 2018-01-16 CN CN202211243959.9A patent/CN115925693B/zh active Active
- 2018-01-16 KR KR1020237032917A patent/KR102659213B1/ko active Active
- 2018-01-16 SM SM20230051T patent/SMT202300051T1/it unknown
- 2018-01-16 CR CR20190332A patent/CR20190332A/es unknown
- 2018-01-16 JP JP2019537377A patent/JP6986086B2/ja active Active
- 2018-01-16 SI SI201830849T patent/SI3571192T1/sl unknown
- 2018-01-16 ES ES18701296T patent/ES2938648T3/es active Active
- 2018-01-16 JO JOP/2019/0174A patent/JOP20190174B1/ar active
- 2018-01-16 SG SG11201906222WA patent/SG11201906222WA/en unknown
- 2018-01-16 EP EP18701296.8A patent/EP3571192B1/en active Active
- 2018-01-16 EA EA201991700A patent/EA037067B1/ru unknown
- 2018-01-16 NZ NZ756069A patent/NZ756069A/en unknown
- 2018-01-16 HR HRP20230069TT patent/HRP20230069T1/hr unknown
- 2018-01-16 AU AU2018209667A patent/AU2018209667B2/en active Active
- 2018-01-16 UA UAA201909176A patent/UA124246C2/uk unknown
- 2018-01-16 KR KR1020197023855A patent/KR102585048B1/ko active Active
- 2018-01-17 AR ARP180100104A patent/AR110753A1/es unknown
- 2018-01-17 TW TW107101685A patent/TWI753089B/zh active
-
2019
- 2019-07-04 IL IL267851A patent/IL267851B/en unknown
- 2019-07-15 CL CL2019001993A patent/CL2019001993A1/es unknown
- 2019-07-15 MX MX2022002976A patent/MX2022002976A/es unknown
- 2019-07-17 DO DO2019000184A patent/DOP2019000184A/es unknown
- 2019-07-17 EC ECSENADI201951352A patent/ECSP19051352A/es unknown
- 2019-07-17 NI NI201900077A patent/NI201900077A/es unknown
- 2019-07-23 CO CONC2019/0007888A patent/CO2019007888A2/es unknown
- 2019-10-18 ZA ZA2019/06875A patent/ZA201906875B/en unknown
-
2021
- 2021-03-01 US US17/188,097 patent/US11897869B2/en active Active
- 2021-11-26 JP JP2021191658A patent/JP7394820B2/ja active Active
-
2023
- 2023-10-20 JP JP2023180744A patent/JP7626819B2/ja active Active
- 2023-12-13 US US18/538,067 patent/US12473272B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3571192T3 (fi) | Jak1-selektiivisiä inhibiittoreita | |
| JP2020506171A5 (enExample) | ||
| JP2022043059A5 (enExample) | ||
| MX2022001828A (es) | Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr). | |
| EP4529954A3 (en) | Thrb receptor agonist compound and preparation method and use thereof | |
| CY1124329T1 (el) | N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων | |
| IL279800B1 (en) | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical compositions comprising them and use thereof | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| MX374346B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| NZ597647A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| TW200406210A (en) | Processes for preparing substituted pyrimidines | |
| MX2021012849A (es) | Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak. | |
| NZ595989A (en) | Heteroaryl compounds and uses thereof | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
| NZ589843A (en) | Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors | |
| CN103827120A (zh) | 6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂* | |
| EA201692465A1 (ru) | Кристаллические соли (s)-6-((1-ацетилпиперидин-4-ил)амино)-n-(3-(3,4-дигидроизохинолин-2(1h)-ил)-2-гидроксипропил)пиримидин-4-карбоксамида | |
| DK3856341T3 (da) | Krystallinske former af (s)-1-(4-fluorphenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amin og fremgangsmåder til fremstilling deraf | |
| MXPA06000051A (es) | Pirimidinas utiles como moduladores de canales ionicos dependientes de voltaje. | |
| MX2020012376A (es) | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| MX2012003720A (es) | N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos. | |
| RU2017145928A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) |